BIOMAT Database Logo BIOMAT Database Logo

[Refractory idiopathic cold agglutinin disease successfully treated with intermittent high-dose cyclophosphamide]. 2001

M Nakagawa, and T Miyagishima, and T Kamata, and S Arai, and Y Miura, and S Onishi, and A Kishimoto, and Y Kamishima, and G H Choi, and M Kudo, and M Okabe
Department of Internal Medicine, Kushiro-Rosai Hospital.

A 56-year-old woman, who had been suffering from idiopathic cold agglutinin disease and treated unsuccessfully with prednisolone and cyclosporine A for 6 months, was referred to our hospital in November 1998. She was given methylprednisolone pulse therapy followed by low-dose cyclophosphamide, but her anemia did not improve. We then began administration of intermittent high-dose cyclophosphamide (1,200 mg/day, every 4 weeks), and this resulted in a dramatic increase of her hemoglobin level and improvement of her symptoms. She is currently receiving 500 mg of cyclophosphamide every 2 months and showing a good response. Intermittent high-dose cyclophosphamide therapy can be an effective treatment for refractory cold agglutinin disease.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000744 Anemia, Hemolytic, Autoimmune Acquired hemolytic anemia due to the presence of AUTOANTIBODIES which agglutinate or lyse the patient's own RED BLOOD CELLS. Anemia, Hemolytic, Idiopathic Acquired,Autoimmune Haemolytic Anaemia,Autoimmune Hemolytic Anemia,Cold Agglutinin Disease,Hemolytic Anemia, Autoimmune,Acquired Autoimmune Hemolytic Anemia,Anemia, Hemolytic, Cold Antibody,Cold Antibody Disease,Cold Antibody Hemolytic Anemia,Idiopathic Autoimmune Hemolytic Anemia,Agglutinin Disease, Cold,Anaemia, Autoimmune Haemolytic,Anemia, Autoimmune Hemolytic,Autoimmune Haemolytic Anaemias,Autoimmune Hemolytic Anemias,Cold Agglutinin Diseases,Cold Antibody Diseases,Haemolytic Anaemia, Autoimmune
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes

Related Publications

M Nakagawa, and T Miyagishima, and T Kamata, and S Arai, and Y Miura, and S Onishi, and A Kishimoto, and Y Kamishima, and G H Choi, and M Kudo, and M Okabe
Acrocyanosis of cold agglutinin disease successfully treated with antibiotics.
June 1984, Cutis,
M Nakagawa, and T Miyagishima, and T Kamata, and S Arai, and Y Miura, and S Onishi, and A Kishimoto, and Y Kamishima, and G H Choi, and M Kudo, and M Okabe
Severe Refractory Immune Thrombocytopenia Successfully Treated with High-Dose Pulse Cyclophosphamide and Eltrombopag.
January 2015, Case reports in hematology,
M Nakagawa, and T Miyagishima, and T Kamata, and S Arai, and Y Miura, and S Onishi, and A Kishimoto, and Y Kamishima, and G H Choi, and M Kudo, and M Okabe
Refractory cold agglutinin disease successfully treated with daratumumab. A case report and review of literature.
December 2023, Hematology (Amsterdam, Netherlands),
M Nakagawa, and T Miyagishima, and T Kamata, and S Arai, and Y Miura, and S Onishi, and A Kishimoto, and Y Kamishima, and G H Choi, and M Kudo, and M Okabe
A Case of Idiopathic Cold Agglutinin Hemolytic Anemia Successfully Treated With Steroids.
March 2022, Cureus,
M Nakagawa, and T Miyagishima, and T Kamata, and S Arai, and Y Miura, and S Onishi, and A Kishimoto, and Y Kamishima, and G H Choi, and M Kudo, and M Okabe
"Refractory" thrombocytopenic purpura treated successfully with cyclophosphamide.
January 1971, JAMA,
M Nakagawa, and T Miyagishima, and T Kamata, and S Arai, and Y Miura, and S Onishi, and A Kishimoto, and Y Kamishima, and G H Choi, and M Kudo, and M Okabe
Nivolumab-induced cold agglutinin syndrome successfully treated with rituximab.
August 2018, Blood advances,
M Nakagawa, and T Miyagishima, and T Kamata, and S Arai, and Y Miura, and S Onishi, and A Kishimoto, and Y Kamishima, and G H Choi, and M Kudo, and M Okabe
[Cold-agglutinin disease with extremely high cold-agglutinin titers].
November 1967, Zeitschrift fur Immunitatsforschung, Allergie und klinische Immunologie,
M Nakagawa, and T Miyagishima, and T Kamata, and S Arai, and Y Miura, and S Onishi, and A Kishimoto, and Y Kamishima, and G H Choi, and M Kudo, and M Okabe
Idiopathic hypertrophic pachymeningitis successfully treated with intravenous cyclophosphamide.
January 2011, Neurology India,
M Nakagawa, and T Miyagishima, and T Kamata, and S Arai, and Y Miura, and S Onishi, and A Kishimoto, and Y Kamishima, and G H Choi, and M Kudo, and M Okabe
Concomitant cryoglobulinemic vasculitis and cold agglutinin disease successfully treated with bortezomib: A case report.
January 2019, Medicine,
M Nakagawa, and T Miyagishima, and T Kamata, and S Arai, and Y Miura, and S Onishi, and A Kishimoto, and Y Kamishima, and G H Choi, and M Kudo, and M Okabe
[Case of idiopathic cold agglutinin disease].
January 1981, Vrachebnoe delo,
Copied contents to your clipboard!